Why Skin Gets Drier and Itchier After Menopause: What the Barrier Research Shows

• Why does skin feel drier and itchier after menopause?
• What does the actual barrier research measure, and what does it find?
• Does estrogen really change how well skin holds water?
• Why does fulvic acid come up with itch specifically?
• What does shilajit's own research show about this same skin signal?
• How does this compare with what most people reach for first?
• Common questions about dry, itchy skin and shilajit

Why does skin feel drier and itchier after menopause?

Plenty of women notice it around the same time as everything else changes, skin that used to bounce back from a shower now feels tight within the hour, and an itch shows up in places that never itched before. It is easy to blame the season or a new soap. Often that is not it.

Shilajit and its active compound, fulvic acid, connect to this through a specific, measured pathway. Human research has tested shilajit's effect on skin blood flow and the extracellular matrix, the structural mesh that helps skin hold its shape and its moisture. A related topical fulvic acid compound has also been tested directly against itchy, inflamed skin in a human trial. Neither study set out to measure dryness by name, and both land on the biology behind it.

Two barrier jobs, one shared decline

A healthy skin barrier does two jobs at once. It keeps water in, and it keeps irritants and moisture loss to a minimum on the way out. Both jobs depend partly on estrogen, which is why researchers have started measuring skin barrier function specifically in postmenopausal women rather than assuming it simply mirrors skin aging in general.

What does the actual barrier research measure, and what does it find?

Nikoletić and colleagues (2025) measured two specific things in 81 women aged 18 to 65, transepidermal water loss, the rate water escapes through the skin, and skin hydration, a direct reading of moisture in the outer skin layer. Thirty-six participants were in their reproductive years, averaging 27, and 45 were postmenopausal, averaging 57.

The result is more nuanced than a simple before-and-after story, and it is worth reporting exactly as measured.

• Skin hydration was significantly lower in the postmenopausal group compared to reproductive-age women measured in the ovulatory phase of their cycle
• Transepidermal water loss showed no statistically significant difference between the postmenopausal group and the reproductive-age group overall
• Within the reproductive-age women, hydration and water loss both shifted across the menstrual cycle itself, evidence that skin barrier readings move for more than one reason
• The study's authors described existing research in this area as limited and conflicting, and issued a correction after publication on one of their own figures

That last point matters. A published correction is not a red flag when it is handled openly. It is exactly what should happen when a research team catches its own error, and this article reports the corrected version of the findings, not the original.

What "hydration" and "water loss" actually measure

These are not subjective ratings. Skin hydration is typically measured with a corneometer, a small probe that reads the electrical capacitance of the skin's outer layer, which changes with moisture content. Transepidermal water loss is measured with a separate probe that tracks water vapor escaping the skin surface in real time. Both are standard, instrument-based dermatology measurements, not a questionnaire.

Does estrogen really change how well skin holds water?

A separate, older study tested this question more directly by intervening rather than just observing. Piérard-Franchimont and colleagues (1995) enrolled 30 menopausal women, split into two groups of 15. One group received transdermal estrogen therapy. The other received no treatment.

Using a standardized stress test on the skin, the researchers found the water-holding capacity of the stratum corneum, the skin's outermost layer, was significantly higher in the women receiving estrogen. The improvement in that specific measurement is one directly tied to skin barrier function in the dermatology literature.

Between an interventional trial showing estrogen raises water-holding capacity and an observational study showing lower hydration in postmenopausal women, the pattern points the same direction from two different angles, even though neither study alone proves the whole story.

Why does fulvic acid come up with itch specifically?

Gandy and colleagues (2011) ran a randomized, double-blind, placebo-controlled trial testing a topical carbohydrate-derived fulvic acid, related to but not identical to Optimum's oral Altai shilajit, in 36 volunteers with diagnosed eczema, applied twice daily for four weeks.

Both the placebo group and the fulvic acid group showed a significant improvement in overall severity and in redness. The investigator's overall assessment of treatment response, a seven-point clinical rating scale, was significantly better in the fulvic acid group than in the placebo group.

The itch angle, in the researchers' own words

Fulvic acid is naturally acidic. The study authors noted that lowering the pH of skin is itself associated with reduced itch during eczema, separate from fulvic acid's measured anti-inflammatory action. All safety measures in the trial, including blood work, stayed within normal limits, with the only reported side effect a short, mild burning sensation on application.

• 36 volunteers completed a 4-week, double-blind, placebo-controlled trial
• Both groups improved on eczema severity and redness, a common finding when any emollient is applied consistently
• The fulvic acid group scored significantly better on the investigator's overall treatment-response rating
• Lower skin pH from the fulvic acid itself is separately linked to reduced itch in the researchers' discussion
• The only reported side effect was a short-lived burning sensation on application, with no other safety differences from placebo

This is a topical product tested on general eczema, not postmenopausal dryness specifically, and we are not stretching it into a claim it did not make.

What does shilajit's own research show about this same skin signal?

Shilajit's own human trial was not built around barrier function by name. It was built around skin blood flow and the extracellular matrix, the structural scaffold underneath the barrier layer, tested directly in adult women.

Das and colleagues (2019) gave healthy middle-aged women oral shilajit at 125 or 250 milligrams twice daily for 14 weeks, then took real skin biopsies with gene-expression sequencing alongside dermascopic perfusion imaging. At the higher dose, shilajit improved measured skin blood flow compared to baseline and to placebo, and it turned on genes tied to blood-vessel growth and extracellular matrix repair. No adverse effects were reported over the 14 weeks.

That is a mechanism finding in real tissue, not a hydration or itch measurement. It is also not a hormone. Shilajit does not add estrogen to the body. What the research supports is the body's own estrogen signaling, the same signaling tied to the water-holding capacity difference measured in the estrogen trial above.

How does this compare with what most people reach for first?

Most dry-skin advice works entirely from the outside of the skin.

A good moisturizer is not the wrong answer. It is simply working on the surface of a system this article traces one layer deeper, into the blood flow and structural collagen that hold water in the first place.

Shilajit's fulvic acid content is the mechanism behind the skin perfusion and extracellular matrix research described above, sourced from the Altai mountains and third-party lab tested for purity on every batch of Optimum Shilajit. No trial has measured it against dryness or itch directly, and we say that plainly rather than imply a result the research has not shown.